ライフサイエンスコーパス: bowel

1 nsion of Enterobacteriaceae within the large bowel.

2 stended and/or potentially compromised small bowel.

3 ive Crohn's disease was present in the small bowel.

4 available which specifically image the small bowel.

5 approaches in patients with distended small bowel.

6 Small-bowel adenocarcinomas (SBAs) are rare cancers with a sig

7 rding to baseline parenteral support volume, bowel anatomy (group 1, jejunostomy/ileostomy; group 2,

8 ume with baseline parenteral support volume, bowel anatomy, and SBS features.

9 ant risk factor for postinfectious irritable bowel and chronic fatigue syndromes.

10 by the EC cells of the human and mouse small bowel and that it is important for EC cell mechanotransd

11 e isolated from the fetal or postnatal mouse bowel and transplanted into the distal colon of 3- to 4-

12 ents with cirrhosis, can contribute to small-bowel bacterial overgrowth.

13 sign, clustered loops, hurricane eye, small bowel behind the superior mesenteric artery, and right-s

14 GI TB commonly affects the small bowel but is difficult to diagnose due to the challenge

15 ents with polyposis syndromes or other small-bowel cancers, who required small-bowel studies.

16 are generally divided into gastric and small bowel categories, and although individual EBMTs may have

17 performed 2 weeks after a reconstruction of bowel continuity.

18 of blocking their progression and preventing bowel damage and disability.

19 prevalence of paediatric-onset inflammatory bowel disease (diagnosis at age <16 years) were excluded

20 ever, health conditions such as inflammatory bowel disease (IBD) are associated with a reduced mucus

21 plex genetic basis of polygenic inflammatory bowel disease (IBD) as well as Mendelian disease-associa

22 presumably plays a key role in inflammatory bowel disease (IBD) development.

23 s (CDIs) among individuals with inflammatory bowel disease (IBD) have used data from single centers o

24 : Immunosuppressive therapy for inflammatory bowel disease (IBD) in pediatric patients is thought to

25 ed in the diagnostic workup for inflammatory bowel disease (IBD) in pediatric patients.

26 Inflammatory bowel disease (IBD) is a chronic inflammatory disease of

27 Inflammatory bowel disease (IBD) is a chronic inflammatory disorder a

28 Inflammatory bowel disease (IBD) is associated with altered microbiot

29 Inflammatory bowel disease (IBD) is associated with increased intesti

30 Inflammatory bowel disease (IBD) is characterized by dysregulation in

31 Inflammatory bowel disease (IBD) is difficult to diagnose due to nons

32 intestinal inflammation during inflammatory bowel disease (IBD) is poorly defined.

33 question asked by patients with inflammatory bowel disease (IBD) is, "Doctor, what should I eat?" Fin

34 regulated by variants linked to inflammatory bowel disease (IBD) not only outperform genetic risk sco

35 Real-life data on inflammatory bowel disease (IBD) prevalence and costs are scarce.

36 blood samples of patients with inflammatory bowel disease (IBD) receiving anti-TNF therapy.

37 available medical therapies of inflammatory bowel disease (IBD) remains controversial.

38 Children and adolescents with inflammatory bowel disease (IBD) report impairments in daily activiti

39 he increased risks conferred by inflammatory bowel disease (IBD) to the development of colorectal can

40 ecision making in patients with inflammatory bowel disease (IBD) who lose response to anti-TNF therap

41 hronic inflammatory conditions (inflammatory bowel disease (IBD)) can be identified.

42 ciated with Crohn's disease, an inflammatory bowel disease (IBD), and poor survival in allogeneic hem

43 )-associated colitis or without inflammatory bowel disease (IBD), and whether expression levels are a

44 TNF plays an integral role in inflammatory bowel disease (IBD), as evidenced by the dramatic therap

45 sociated with disorders such as inflammatory bowel disease (IBD), but the mechanisms of this process

46 set and enhance the severity of inflammatory bowel disease (IBD).

47 e been associated with risk for inflammatory bowel disease (IBD).

48 ased risk of or protection from inflammatory bowel disease (IBD).

49 -PMPA) as a novel treatment for inflammatory bowel disease (IBD).

50 g its efficacy in patients with inflammatory bowel disease (IBD).

51 y 75% of patients have comorbid inflammatory bowel disease (IBD).

52 macrophages in a mouse model of inflammatory bowel disease (IBD).

53 een associated with the risk of inflammatory bowel disease (IBD).

54 s that are linked to asthma and inflammatory bowel disease (IBD).

55 adenomatosis polyposis (FAP) or inflammatory bowel disease (IBD).

56 e incidence and pathogenesis of inflammatory bowel disease (IBD).

57 key role in the pathogenesis of inflammatory bowel disease (IBD).

58 megalovirus (CMV) infection and inflammatory bowel disease (IBD).

59 Infantile-onset inflammatory bowel disease (IO IBD) is an invalidating illness with a

60 Pediatric inflammatory bowel disease (pIBD) is a chronic heterogeneous disorder

61 er models, including autoimmune inflammatory bowel disease and allogeneic graft-versus-host disease.

62 se models, including a model of inflammatory bowel disease and an inflammatory arthritis model.

63 een associated with early-onset inflammatory bowel disease and colon cancer.

64 s (ETBF) has been implicated in inflammatory bowel disease and colorectal cancer; however, colonizati

65 ow to best manage patients with inflammatory bowel disease and flat low-grade dysplasia (fLGD) in the

66 for research into prevention of inflammatory bowel disease and innovations in health-care systems to

67 Disorders, such as inflammatory bowel disease and irritable bowel syndrome, are associat

68 osus (SLE), Sjogren's syndrome, inflammatory bowel disease and multiple sclerosis.

69 inflammatory disorders such as inflammatory bowel disease and rheumatoid arthritis.

70 seases such as atherosclerosis, inflammatory bowel disease and systemic lupus erythematosus.

71 reatment effects in early-onset inflammatory bowel disease are less certain.

72 DC-LMP1/CD40 chimeras developed inflammatory bowel disease characterized by massive transmural influx

73 tic association in the Manitoba Inflammatory Bowel Disease Cohort Study was conducted through the gen

74 The prevalence of inflammatory bowel disease exceeded 0.3% in North America, Oceania, a

75 ng surveillance colonoscopy for inflammatory bowel disease from 1990 to 2015 at the University of Cal

76 t the turn of the 21st century, inflammatory bowel disease has become a global disease with accelerat

77 In small studies, inflammatory bowel disease has been associated with the increased pre

78 ia management for patients with inflammatory bowel disease has changed since this first case report,

79 volving genetic architecture of inflammatory bowel disease has deepened our understanding of its path

80 of the genetic underpinnings of inflammatory bowel disease has made great progress since the identifi

81 general population, the risk of inflammatory bowel disease in children was 80 times higher, and the r

82 able or decreasing incidence of inflammatory bowel disease in North America and Europe.

83 the data on the concurrence of inflammatory bowel disease in patients with HS are limited.

84 Inflammatory bowel disease is a global disease in the 21st century.

85 Inflammatory bowel disease is associated with psychological comorbidi

86 Heritability of early-onset inflammatory bowel disease is hypothesised to be between that of infa

87 dence of early-onset paediatric inflammatory bowel disease is increasing worldwide.

88 However, the effect of AS II on inflammatory bowel disease is unknown.

89 benefits of using each class of inflammatory bowel disease medication.

90 tivity of TR1 cells in a murine inflammatory bowel disease model, a model that resembles the trials p

91 e of the heavy burden of severe inflammatory bowel disease on patients' health and quality of life, a

92 in a mouse model of colitis and inflammatory bowel disease patients, and this results in dysregulated

93 lated in inflamed biopsies from inflammatory bowel disease patients.

94 ed with the histology scores of inflammatory bowel disease patients.

95 iorate rheumatoid arthritis and inflammatory bowel disease provide a path for using electrons as a th

96 come was quality of life on the Inflammatory Bowel Disease Questionnaire (IBDQ) at 12 months.

97 gy that can be used to optimize inflammatory bowel disease therapeutics.

98 disease, ulcerative colitis, or inflammatory bowel disease unclassified before the age of 10 years, t

99 6 with CD, 583 with UC, and 116 inflammatory bowel disease unclassified) and 5002 individuals without

100 ic risk (e.g., genetic risk for inflammatory bowel disease was negatively correlated with plasma cyst

101 ve risk of relapse of quiescent inflammatory bowel disease with psychological therapy versus control

102 ve TDM (in patients with active inflammatory bowel disease) to guide treatment changes compared with

103 eases (rheumatoid arthritis and inflammatory bowel disease), metabolic diseases (atherosclerosis, dia

104 receiving treatment for chronic inflammatory bowel disease, 12.1% of the participants were recruited

105 presence and risk of new-onset inflammatory bowel disease, although the prevalence remained low.

106 lthy controls, 40 controls with inflammatory bowel disease, and 327 consecutive patients with cirrhos

107 ted respiratory disease (AERD), inflammatory bowel disease, and acute respiratory distress syndrome.

108 stridium difficile infection or inflammatory bowel disease, and most (87%) were non-randomized contro

109 om women without a diagnosis of inflammatory bowel disease, celiac disease, or liver disease, endosco

110 educe many clinical features of inflammatory bowel disease, complete mucosal healing occurs in fewer

111 e and other diseases, including inflammatory bowel disease, Crohn's disease and rheumatoid arthritis.

112 logic conditions, malignancies, inflammatory bowel disease, dermatologic conditions, or solid-organ o

113 es), and disease features (with inflammatory bowel disease, mesenteric vascular diseases, or other co

114 is of many disorders, including inflammatory bowel disease, sepsis, and inflammatory arthritis.

115 ve identified 215 risk loci for inflammatory bowel disease, thereby uncovering fundamental aspects of

116 ive effect in the management of inflammatory bowel disease, treatment effects in early-onset inflamma

117 mportant therapeutic target for inflammatory bowel disease-associated diarrhea.

118 ion studies have identified 200 inflammatory bowel disease-associated loci, but few have been conclus

119 l adenocarcinoma, as well as in inflammatory bowel disease-associated SBAs.

120 s, such as allergy, asthma, and inflammatory bowel disease.

121 ase pathway in the pathogenesis of irritable bowel disease.

122 on and treatment strategies for inflammatory bowel disease.

123 ole of TDM in the management of inflammatory bowel disease.

124 hemoprevention in patients with inflammatory bowel disease.

125 tive colitis, one form of human inflammatory bowel disease.

126 isease-modifying therapeutic of inflammatory bowel disease.

127 th vedolizumab in patients with inflammatory bowel disease.

128 ntribute to the pathogenesis of inflammatory bowel disease.

129 IL10R) develop very early onset inflammatory bowel disease.

130 d affect the natural history of inflammatory bowel disease.

131 mportant therapeutic targets in inflammatory bowel disease.

132 T cell therapy in patients with inflammatory bowel disease.

133 uality of life in patients with inflammatory bowel disease.

134 ment of mucosal inflammation or inflammatory bowel disease.

135 new option in the treatment of inflammatory bowel disease.

136 odium sulfate mediated model of inflammatory bowel disease.

137 uality of life in patients with inflammatory bowel disease.

138 r a therapeutic avenue in treating irritable bowel disease.

139 previously reported cases with inflammatory bowel disease.

140 its effects in mouse models of inflammatory bowel diseases (IBD) and intestinal mucosal healing.

141 r immune responses that mediate inflammatory bowel diseases (IBD) in humans and enterocolitis in mice

142 BACKGROUND & AIMS: Inflammatory bowel diseases (IBD) increase risk for colorectal cancer

143 BACKGROUND & AIMS: Diagnosis of inflammatory bowel diseases (IBD) is increasing among elderly persons

144 f children newly diagnosed with inflammatory bowel diseases (IBD) to learn more about pathogenesis.

145 for therapeutic application in inflammatory bowel diseases (IBD) yet understanding of the underlying

146 ts metabolites in patients with inflammatory bowel diseases (IBD), and study their association with c

147 Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and

148 Inflammatory bowel diseases (IBD), such as Crohn disease and ulcerati

149 Cs systemically administered in inflammatory bowel diseases (IBD).

150 Inflammatory bowel diseases (IBDs) are a set of complex and debilitat

151 Inflammatory bowel diseases (IBDs) are chronic and impose significant

152 sights into the pathogenesis of inflammatory bowel diseases (IBDs) have provided important informatio

153 BACKGROUND & AIMS: Inflammatory bowel diseases (IBDs) increase the risk of colorectal ca

154 robiome plays a central role in inflammatory bowel diseases (IBDs) pathogenesis and propagation.

155 lammatory conditions, including inflammatory bowel diseases (IBDs), herein we investigate expression

156 or nonallopathic therapies, for inflammatory bowel diseases (IBDs).

157 e altered during development of inflammatory bowel diseases (IBDs).

158 = 74) or from patients without inflammatory bowel diseases (n = 22), to measure levels of GATA3.

159 Inflammatory bowel diseases are chronic gastrointestinal inflammatory

160 Strategies for management of inflammatory bowel diseases are shifting from simple control of sympt

161 nority of patients with SBS and inflammatory bowel diseases had colon-in-continuity (10.5% [n = 2/19]

162 AIMS: Diarrhea associated with inflammatory bowel diseases has been associated with increased levels

163 estinal mucosa of patients with inflammatory bowel diseases has reduced expression of solute carrier

164 Inflammatory bowel diseases involve the dynamic interaction of host g

165 The pathology of inflammatory bowel diseases is driven by the inflammatory signaling p

166 the genetic architecture of the inflammatory bowel diseases ulcerative colitis and Crohn's disease, w

167 inal tissues from patients with inflammatory bowel diseases vs controls, we found that reactivity to

168 atory disease) and 30ng/mL (for inflammatory bowel diseases) CRP in 1000-fold diluted blood respectiv

169 , diabetes, obesity, arthritis, inflammatory bowel diseases, and even neuropsychiatric disorders.

170 ative colitis are heterogeneous inflammatory bowel diseases, and therapeutic requirements vary among

171 of this serious complication of inflammatory bowel diseases, as well as factors that predict its prog

172 nt roles in human metabolic and inflammatory bowel diseases, but a role in host response to microbes

173 d antibiotics for patients with inflammatory bowel diseases, but are these immunotherapies ready for

174 These include inflammatory bowel diseases, irritable bowel syndrome, and metabolic

175 In patients with inflammatory bowel diseases, microbiota-reactive CD4(+) T cells were

176 atment can alter progression of inflammatory bowel diseases, the importance of examining objective si

177 otective role in infectious and inflammatory bowel diseases, whereas both beneficial and detrimental

178 total of 27 pouch patients with inflammatory bowel diseases, who underwent pelvic MRI-DIXON and CT sc

179 Inflammatory bowel diseases-associated fibrosis was seen as an irreve

180 elvic inflammatory disease, and inflammatory bowel diseases-at a concentration range of 1-100ng/mL in

181 to resolve gut inflammation in inflammatory bowel diseases.

182 is, cardiovascular disease, and inflammatory bowel diseases.

183 ical feature of colitis and the inflammatory bowel diseases.

184 ay offer therapeutic options in inflammatory bowel diseases.

185 patterns associated with human inflammatory bowel diseases.

186 contributes to pathogenesis of inflammatory bowel diseases.

187 tinal fibrosis in patients with inflammatory bowel diseases.

188 of action are seen in the gastric and small bowel EBMTs, respectively.

189 C1 inhibitor deficiency and patients with bowel edema only were excluded.

190 lly within EC cells of human and mouse small bowel epithelium.

191 and 2011 answered detailed questionnaires on bowel function and QoL [Pediatric Quality of Life Invent

192 olled long-term follow-up studies evaluating bowel function and QoL are lacking.

193 at the EC cells in the human and mouse small bowel GI epithelium selectively express the mechanosensi

194 Enteric neural cells transplanted into the bowel give rise to multiple functional types of neurons

195 function, and low grade inflammation of the bowel have been hypothesized.

196 troke, pulmonary embolism, renal failure, or bowel infarction) within 30 days after surgery.

197 Other causes included: - 4 patients with bowel inflammation (including complications of neoplasti

198 einemia, malabsorption, and less frequently, bowel inflammation, recurrent infections, and angiopathi

199 more common, yet might increase the risk of bowel injury given the distended and/or potentially comp

200 We induced small bowel injury in rats using high- (15 mg/kg), intermediat

201 We estimated the odds of bowel intervention after adjusting for patient and clini

202 tment for potential confounders, the odds of bowel intervention among patients treated laparoscopical

203 The incidence of bowel intervention was 53.5% versus 43.4% in laparoscopi

204 The primary outcome was incidence of bowel intervention, defined as intraoperative enterotomy

205 There were no clinical signs of bowel ischaemia during the follow-up period.

206 omy findings were both compatible with small bowel ischemia-necrosis and perforation.

207 al crest cells (ENCCs) to fully colonize the bowel, leading to bowel obstruction and megacolon.

208 irth weight, age, PN duration, and remaining bowel length.

209 niated abdominal organs including the liver, bowel loops and the ectopic cardia.

210 ating the entire length of overlapping small bowel loops with traditional diagnostic methods like Bar

211 regions (aorta, liver, spleen, kidney, small bowel, lumbar vertebra, psoas muscle, urinary bladder) a

212 reasonably accurate evaluation of the small bowel lumen, wall, perienteric tissues, and solid organs

213 ological alterations in and around the small bowel, MDCTE seems to be an attractive modality for pati

214 a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid

215 A responder had at least three spontaneous bowel movements (SBMs) per week with an increase from ba

216 ream functional effects in the healthy large-bowel mucosa remain to be investigated.

217 tion of subjects developing at least 1 small-bowel mucosal break at week 2.

218 erwent isolated allograft enterectomy due to bowel necrosis.

219 large cohort of patients with adhesive small bowel obstruction (SBO) managed operatively.

220 shed CT signs of IH: mesenteric swirl, small-bowel obstruction (SBO), mushroom sign, clustered loops,

221 ely identify strangulation in adhesive small bowel obstruction (SBO).

222 CCs) to fully colonize the bowel, leading to bowel obstruction and megacolon.

223 operative ileus, deep vein thrombosis, small bowel obstruction, urinary stricture, urine leak, hernia

224 g sensitization of neuronal signaling in the bowel of patients with PI-IBS.

225 monstrate that neuronal signaling within the bowel of PI-IBS patients is sensitized 2 years after the

226 no meaningful differences existed in either bowel or hormonal function beyond 12 months or in in oth

227 No clinically significant differences for bowel or hormone function were noted beyond 12 months.

228 quamous cell carcinoma, cancers of the small bowel, pancreas, and colorectum show the highest rates a

229 has been reported in cases of kidney, liver, bowel, pancreas, heart, lung, and stem-cell transplant,

230 Delayed small bowel perforation following BAT is thought to occur seco

231 is is the first case report of delayed small bowel perforation following BAT with extensive portomese

232 re of any other case report of delayed small bowel perforation following BAT without signs of intraab

233 Isolated small bowel perforation following blunt abdominal trauma (BAT)

234 idity and mortality rates, and delayed small bowel perforation is even rarer.

235 A on colonoscopy complications, specifically bowel perforation, aspiration pneumonia, and splenic inj

236 The primary outcome was bowel perforation, defined using a validated algorithm.

237 surgery for colon cancer without mechanical bowel preparation (n = 18).

238 index examination with fair or poor quality bowel preparation (RR vs excellent quality, 2.16; 95% CI

239 Discomfort associated with bowel preparation was higher among CT colonography than

240 idual findings), and a CF-specific intensive bowel preparation.

241 on and irritation, urinary incontinence, and bowel problems-each scored from 0 (no dysfunction) to 10

242 for urinary incontinence, and 5.7 to 6.1 for bowel problems.

243 National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 compared TC6, TA

244 zumab (National Surgical Adjuvant Breast and Bowel Project C-08 trial).

245 The use of a bowel protocol was associated with a trend toward a redu

246 ntrol trials are needed to determine whether bowel protocols impact patient-important outcomes in cri

247 systematic review to determine the impact of bowel protocols in critically ill adults.

248 s for randomized controlled trials comparing bowel protocols to control (placebo, no protocol, or usu

249 We set out to compare the incidence of bowel repair and/or resection in a large cohort of patie

250 After massive small bowel resection, tuft cells and Tm were diminished due t

251 miurgent repair, and need for intraoperative bowel resection.

252 e enterotomy, suture repair of intestine, or bowel resection.

253 SCR), which is congenital obstruction of the bowel, results from a failure of enteric nervous system

254 During surgery a bowel strangulation was revealed.

255 ther small-bowel cancers, who required small-bowel studies.

256 The absolute risk of bowel surgery was higher in the elderly than in the gene

257 s similar in elderly and adult patients, but bowel surgery was more common in the elderly (13% after

258 A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing

259 Ongoing bowel symptoms were present in 16.3% of patients with IB

260 apy (20.5 [95% CI, 15.1-25.9]); and worsened bowel symptoms with external beam radiotherapy (4.9 [95%

261 mpaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated wit

262 ntestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) into German and to evaluate it

263 trointestinal Symptom Rating Scale Irritable Bowel Syndrome (GSRS-IBS) version.

264 apy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal pain or fu

265 tudies report on the prevalence of irritable bowel syndrome (IBS) and its correlates in the Middle Ea

266 RD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common functional gastrointesti

267 p between giardiasis diagnosis and irritable bowel syndrome (IBS) diagnosis.

268 Irritable bowel syndrome (IBS) is a gut-brain disorder involving a

269 BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is associated with intestinal dysbi

270 Irritable bowel syndrome (IBS) is one of the most common functiona

271 ssion and evaluate the severity of irritable bowel syndrome (IBS).

272 icrobiota and clinical features of irritable bowel syndrome (IBS).

273 hypersensitivity is one feature of irritable bowel syndrome (IBS).

274 ach year, and is a risk factor for irritable bowel syndrome (IBS).

275 s (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism of action

276 gut microbiota in post-infectious irritable bowel syndrome (PI-IBS) is convincing.

277 GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed.

278 nteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, increasing

279 ed to determine the epidemiology of narcotic bowel syndrome and delineate the most efficacious detoxi

280 to be most genetically similar to irritable bowel syndrome and most environmentally similar to cysti

281 options for diarrhoea-predominant irritable bowel syndrome have had not very promising results; most

282 Although narcotic bowel syndrome is rarely diagnosed, given the current ep

283 Patients with short bowel syndrome lack sufficient functional intestine to s

284 s functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C).

285 clude inflammatory bowel diseases, irritable bowel syndrome, and metabolic (i.e. obesity, non-alcohol

286 as inflammatory bowel disease and irritable bowel syndrome, are associated with exaggerated visceral

287 co-morbid somatic disorders, e.g. irritable bowel syndrome, fibromyalgia, or migraine.

288 ue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatment, and pr

289 is one of the causes suggested for irritable bowel syndrome, particularly for the diarrhoea-predomina

290 o be approved for the treatment of irritable bowel syndrome-diarrhoea is rifaximin, which was approve

291 hreatening consequences, such as mesenteric, bowel, ureteral, and/or bladder obstruction.

292 Among the strangulated cases, reduced bowel wall enhancement (odds ratio, 3.9; 95% CI: 1.3, 12

293 lation in the multivariate analysis: reduced bowel wall enhancement (odds ratio, 7.8; 95% confidence

294 ore that combines three CT findings (reduced bowel wall enhancement, a closed-loop mechanism, and dif

295 matic hernia, with ultrasound signs of acute bowel wall necrosis.

296 crotizing enterocolitis (NEC) in neonates or bowel wall rupture in older children.

297 large amount of retained stool in the colon, bowel wall thickening and infiltration of peri-colonic f

298 ctic acid level secondary to ischemia of the bowel wall with CT scan findings aid in establishing the

299 hat is, diverticulae) due to weakness in the bowel wall, which can become infected and inflamed causi

300 onal innervation of the smooth muscle of the bowel wall.